FDA Approves Lyfgenia (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

SOMERVILLE, Mass.--(BUSINESS WIRE)--Dec. 8, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird bio” or“bluebird”) today announced the U.S. Food and Drug Administration (FDA) has approved Lyfgenia (pronounced as...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news